Skip to content
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.

Earnings

JSR's operating profit more than doubles on chip materials as Crown Bioscience sale falls through

JSR's operating profit rose 121.6% to ¥42.0bn in the half to September, led by advanced-chip materials, while the Crown Bioscience sale to an Adicon group company was terminated and its financial effect remains under review.

By Tokyo Brief DeskNov 16, 2026, 20:44 JST3 min read
Photoresist bottles and wafer carriers on one side of a cleanroom shelf and a tray of sample vials with an empty slot on the other.

JSR's operating profit rose 121.6% to ¥42.0bn in the six months to September 2026, with electronic materials for advanced chips doing the heavy lifting. In the same half-year report, filed on 16 November, the company disclosed that its agreed sale of Crown Bioscience has been cancelled.

Chips carry the half

Revenue grew 27.8% to ¥265.1bn. Profit before tax reached ¥23.7bn, against ¥3.1bn a year earlier, and profit attributable to owners of the parent rose to ¥15.7bn from ¥3.4bn.

The digital solutions segment produced most of it: revenue of ¥152.3bn, up 29.6%, and operating profit of ¥35.8bn, up 62.7%. JSR attributes the gain to strong demand for advanced-semiconductor materials in Asian markets, and says AI-related demand in the chip market ran stronger than expected. Those explanations are the company's own.

Synthetic resins improved from a small base. Operating profit rose 368.9% to ¥3.5bn as JSR passed higher raw-material costs, which it links to rising crude prices amid Middle East tensions, into selling prices.

JSR segment results, six months to September 2026
Revenue change is year on year. Operating profit is segment profit before unallocated corporate costs.
SegmentRevenueRevenue changeOperating profit
Digital solutions¥152.3bn+29.6%¥35.8bn
Synthetic resins¥51.9bn+13.7%¥3.5bn
Life sciences¥60.6bn+48.8%¥3.7bn (from a ¥4.9bn loss)

Life sciences: a swing with a lump sum in it

The life sciences segment moved from an operating loss of ¥4.9bn to a profit of ¥3.7bn on revenue of ¥60.6bn. JSR says the CDMO business, which makes biologic drugs under contract, booked revenue from past transactions with customers in one lump at KBI Biopharma, which lifted both revenue and profit. Cost control in its CRO business also helped. The report does not give the size of the lump sum.

Segment profits total ¥43.2bn, but consolidated operating profit is ¥42.0bn after ¥1.1bn of unallocated corporate costs. JSR describes life sciences as a non-core business and says it continues to consider all options for it.

The sale that did not close

JSR Life Sciences, LLC had agreed on 13 November 2025 to sell all shares in its subsidiary Crown Bioscience International to Miramar Lifesciences Limited, a group company of Hong Kong-listed Adicon Holdings. The parties agreed to terminate the contract effective 13 November 2026. JSR says the closing conditions were not expected to be met within the period originally assumed.

Crown Bioscience stays with JSR Life Sciences, and JSR says it will look for a new buyer. The effect on this fiscal year's consolidated results is, in JSR's words, under review, so the report puts no loss or gain on the cancelled deal. It also gives no price for the original sale.

The independent auditor's interim review report carries an emphasis-of-matter paragraph on the termination. The paragraph states that it does not affect the auditor's conclusion, which found nothing to suggest the interim statements were not fairly presented in all material respects. An interim review uses more limited procedures than a full audit.

Balance sheet

JSR repaid ¥56.1bn of long-term borrowings in the half and received ¥28.8bn from business transfers. Total liabilities fell to ¥659.3bn, and the equity ratio attributable to owners of the parent stood at 38.1%, against 34.8% at the end of March.